Volume 11, Number 1—January 2005
Research
Multidrug-Resistant Acinetobacter baumannii
Aharon Abbo*, Shiri Navon-Venezia*, Orly Hammer-Muntz*, Tami Krichali*, Yardena Siegman-Igra*, and Yehuda Carmeli*
Table 3
Multivariate analysis for risk factors for Acinetobacter baumannii*†
| Parameter‡ | OR | 95% CI | p value |
|---|---|---|---|
| Male sex | 3.84 | 1.63–8.99 | 0.002 |
| Ischemic heart disease | 3.35 | 1.44–7.77 | 0.005 |
| Mechanical ventilation | 6.27 | 2.27–17.33 | <0.001 |
| Penicillin use§ | 0.38 | 0.16–0.90 | 0.029 |
| Metronidazole use | 2.33 | 0.98–5.83 | 0.071 |
| Any home antimicrobial drug treatment | 4.74 | 1.31–17.15 | 0.018 |
*OR, odds ratio; CI, confidence interval.
†Adjusted for length of hospital stay prior to entry to the study.
‡All parameters had been present before A. baumannii identification.
§Including semisynthetics with or without a β-lactamase inhibitor (never sulbactam).
Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.